BioMarin Pharmaceutical (MEX:BMRN) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:BMRN BioMarin Pharmaceutical Inc MEX:BMRN
79 GF Score
Price MXN1,105.00
GF Value MXN1,393.76
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is BioMarin Pharmaceutical Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


BioMarin Pharmaceutical  (MEX:BMRN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


BioMarin Pharmaceutical Cyclically Adjusted PS Ratio Related Terms


BioMarin Pharmaceutical Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for BioMarin Pharmaceutical's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMarin Pharmaceutical Cyclically Adjusted PS Ratio Chart

BioMarin Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.00 12.86 7.35 8.10 4.17

BioMarin Pharmaceutical Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.70 4.28 4.14 4.02 3.81

MEX:BMRN vs MDGL, CORT, ARWR: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, BioMarin Pharmaceutical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioMarin Pharmaceutical Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BioMarin Pharmaceutical's Cyclically Adjusted PS Ratio falls into.


MEX:BMRN
79GF Score
BioMarin Pharmaceutical Inc MEX:BMRN
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioMarin Pharmaceutical Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

BioMarin Pharmaceutical's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, BioMarin Pharmaceutical's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=89.127/333.9520*333.9520
=89.127

Current CPI (Jun. 2026) = 333.9520.

BioMarin Pharmaceutical Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 31.142 241.428 43.077
201612 34.569 241.432 47.816
201703 35.289 243.801 48.338
201706 33.651 244.955 45.877
201709 34.503 246.819 46.683
201712 39.288 246.524 53.221
201803 40.523 249.554 54.228
201806 41.350 251.989 54.800
201809 41.354 252.439 54.707
201812 39.275 251.233 52.206
201903 43.090 254.202 56.608
201906 40.966 256.143 53.410
201909 47.542 256.759 61.835
201912 47.279 256.974 61.442
202003 53.094 258.115 68.694
202006 54.367 257.797 70.427
202009 53.014 260.280 68.020
202012 50.288 260.474 64.474
202103 53.970 264.877 68.044
202106 54.464 271.696 66.944
202109 44.643 274.310 54.350
202112 50.276 278.802 60.221
202203 54.060 287.504 62.794
202206 56.467 296.311 63.640
202209 53.454 296.808 60.143
202212 54.588 296.797 61.422
202303 56.917 301.836 62.973
202306 53.970 305.109 59.072
202309 52.307 307.789 56.753
202312 59.136 306.746 64.381
202403 55.427 312.332 59.264
202406 60.941 314.175 64.777
202409 71.282 315.301 75.499
202412 75.465 315.605 79.852
202503 76.103 319.799 79.471
202506 81.978 322.561 84.873
202509 76.338 324.800 78.489
202512 85.219 324.054 87.822
202603 69.168 330.213 69.951
202606 89.127 333.952 89.127

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is BioMarin Pharmaceutical (MEX:BMRN) Overvalued in 2026?

Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued. The current stock price of MXN1,105.00 is trading 20.7% below its estimated GF Value™ of MXN1,393.76. GuruFocus considers BioMarin Pharmaceutical to be Modestly Undervalued.

Key valuation signals for MEX:BMRN:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: MXN1,393.76 vs. price of MXN1,105.00 (20.7% below fair value)
  • GF Score™: 79/100 with 5 warning signs

No single metric tells the full story. See the MEX:BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioMarin Pharmaceutical Business Description

Address 770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
79GF Score

Get the complete analysis for MEX:BMRN

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,105.00
Price
MXN1,393.76
GF Value